関連レポート

血液検査の世界市場：2031年予測

出版元：Transparency Market Research  出版元について

発行年：2024年2月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 194ページになります。

商品コード：TMR227

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

血漿分画製剤の世界市場規模は2022年で241億ドル、2031年末までに426億ドルへと拡大し、2023年から2031年にかけての市場の平均年成長率は6.7%で推移することが見込まれています。

当レポートでは、血漿分画製剤の市場予測-2031年、各種セグメント別市場分析(製品タイプ別、用途別、国地域別、等)、市場ダイナミクス、パイプライン分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。


【レポート構成概要】
■血漿分画製剤の世界市場予測2017-2031年
・市場規模(US$)

■製品タイプ別、市場-2031年
免疫グロブリン
・免疫グロブリン静脈注射
・皮下免疫グロブリン

凝固因子濃縮製剤
・第VIII因子
・第IX因子
・第XIII因子
・プロトロンビン複合体濃縮製剤
・フォンウィルブランド因子（VWF）
・フィブリノゲン濃縮製剤

アルブミン
プロテアーゼ阻害剤
その他の血漿製剤
※(市場規模US$)

■用途別、市場-2031年
・神経学
・免疫学
・血液学
・クリティカルケア
・呼吸器内科
・その他
※(市場規模US$)

■エンドユーザー別、市場-2031年
・病院、クリニック
・臨床研究所
・学術機関
※(市場規模US$)

■主要国地域別市場-2031年
北米
・米国、カナダ
欧州
・英国、ドイツ、フランス、イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド、オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
・市場ダイナミクス（促進要因、障壁、機会）
・パイプライン分析
・主要技術/ブランド分析
・競合状況

■血漿分画製剤の主要企業プロフィール動向
・CSL Limited
・武田薬品工業株式会社
・Sanquin
・Biotest AG
・GRIFOLS
・Baxter International Inc.
・Kedrion
・Octapharma AG
・Taibang Biological Group Co., Ltd

（全194頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Plasma Fractionation Market

4. Market Overview
4.1. Introduction
4.1.1. Technology, Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Plasma Fractionation Market Analysis and Forecast, 2017–2031

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Technology, /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Plasma Fractionation Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2017–2031
6.3.1. Immunoglobulin
6.3.1.1. Intravenous Immunoglobulin
6.3.1.2. Subcutaneous Immunoglobulin
6.3.2. Coagulation Factor Concentrates
6.3.2.1. Factor VIII
6.3.2.2. Factor IX
6.3.2.3. Factor XIII
6.3.2.4. Prothrombin Complex Concentrates
6.3.2.5. Von Willebrand Factor (VWF)
6.3.2.6. Fibrinogen Concentrates
6.3.3. Albumin
6.3.4. Protease Inhibitors
6.3.5. Other Plasma Products
6.4. Market Attractiveness Analysis, by Product Type,

7. Plasma Fractionation Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Neurology
7.3.2. Immunology
7.3.3. Hematology
7.3.4. Critical Care
7.3.5. Pulmonology
7.3.6. Others
7.4. Market Attractiveness Analysis, by Application

8. Plasma Fractionation Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals and Clinics
8.3.2. Clinical Research Laboratories
8.3.3. Academic Institutes
8.4. Market Attractiveness Analysis, by Application

9. Plasma Fractionation Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Plasma Fractionation Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Product Type, 2017–2031
10.3.1. Immunoglobulin
10.3.1.1. Intravenous Immunoglobulin
10.3.1.2. Subcutaneous Immunoglobulin
10.3.2. Coagulation Factor Concentrates
10.3.2.1. Factor VIII
10.3.2.2. Factor IX
10.3.2.3. Factor XIII
10.3.2.4. Prothrombin Complex Concentrates
10.3.2.5. Von Willebrand Factor (VWF)
10.3.2.6. Fibrinogen Concentrates
10.3.3. Albumin
10.3.4. Protease Inhibitors
10.3.5. Other Plasma Products
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Neurology
10.4.2. Immunology
10.4.3. Hematology
10.4.4. Critical Care
10.4.5. Pulmonology
10.4.6. Others
10.5. Market Value Forecast, by End-user, 2017–2031
10.5.1. Hospitals and Clinics
10.5.2. Clinical Research Laboratories
10.5.3. Academic Institutes
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Product Type,
10.7.2. By Application
10.7.3. By End-user
10.7.4. By Country

11. Europe Plasma Fractionation Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Product Type, 2017–2031
11.3.1. Immunoglobulin
11.3.1.1. Intravenous Immunoglobulin
11.3.1.2. Subcutaneous Immunoglobulin
11.3.2. Coagulation Factor Concentrates
11.3.2.1. Factor VIII
11.3.2.2. Factor IX
11.3.2.3. Factor XIII
11.3.2.4. Prothrombin Complex Concentrates
11.3.2.5. Von Willebrand Factor (VWF)
11.3.2.6. Fibrinogen Concentrates
11.3.3. Albumin
11.3.4. Protease Inhibitors
11.3.5. Other Plasma Products
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Neurology
11.4.2. Immunology
11.4.3. Hematology
11.4.4. Critical Care
11.4.5. Pulmonology
11.4.6. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals and Clinics
11.5.2. Clinical Research Laboratories
11.5.3. Academic Institutes
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Product Type
11.7.2. By Application
11.7.3. By End-user
11.7.4. By Country/Sub-region

12. Asia Pacific Plasma Fractionation Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Product Type, 2017–2031
12.3.1. Immunoglobulin
12.3.1.1. Intravenous Immunoglobulin
12.3.1.2. Subcutaneous Immunoglobulin
12.3.2. Coagulation Factor Concentrates
12.3.2.1. Factor VIII
12.3.2.2. Factor IX
12.3.2.3. Factor XIII
12.3.2.4. Prothrombin Complex Concentrates
12.3.2.5. Von Willebrand Factor (VWF)
12.3.2.6. Fibrinogen Concentrates
12.3.3. Albumin
12.3.4. Protease Inhibitors
12.3.5. Other Plasma Products
12.4. Market Value Forecast, by Application, 2017–2031
12.4.1. Neurology
12.4.2. Immunology
12.4.3. Hematology
12.4.4. Critical Care
12.4.5. Pulmonology
12.4.6. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals and Clinics
12.5.2. Clinical Research Laboratories
12.5.3. Academic Institutes
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Product Type,
12.7.2. By Application
12.7.3. By End-user
12.7.4. By Country/Sub-region

13. Latin America Plasma Fractionation Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Product Type, 2017–2031
13.3.1. Immunoglobulin
13.3.1.1. Intravenous Immunoglobulin
13.3.1.2. Subcutaneous Immunoglobulin
13.3.2. Coagulation Factor Concentrates
13.3.2.1. Factor VIII
13.3.2.2. Factor IX
13.3.2.3. Factor XIII
13.3.2.4. Prothrombin Complex Concentrates
13.3.2.5. Von Willebrand Factor (VWF)
13.3.2.6. Fibrinogen Concentrates
13.3.3. Albumin
13.3.4. Protease Inhibitors
13.3.5. Other Plasma Products
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Neurology
13.4.2. Immunology
13.4.3. Hematology
13.4.4. Critical Care
13.4.5. Pulmonology
13.4.6. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals and Clinics
13.5.2. Clinical Research Laboratories
13.5.3. Academic Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Product Type,
13.7.2. By Application
13.7.3. By End-user
13.7.4. By Country/Sub-region

14. Middle East & Africa Plasma Fractionation Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Product Type, 2017–2031
14.3.1. Immunoglobulin
14.3.1.1. Intravenous Immunoglobulin
14.3.1.2. Subcutaneous Immunoglobulin
14.3.2. Coagulation Factor Concentrates
14.3.2.1. Factor VIII
14.3.2.2. Factor IX
14.3.2.3. Factor XIII
14.3.2.4. Prothrombin Complex Concentrates
14.3.2.5. Von Willebrand Factor (VWF)
14.3.2.6. Fibrinogen Concentrates
14.3.3. Albumin
14.3.4. Protease Inhibitors
14.3.5. Other Plasma Products
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Neurology
14.4.2. Immunology
14.4.3. Hematology
14.4.4. Critical Care
14.4.5. Pulmonology
14.4.6. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals and Clinics
14.5.2. Clinical Research Laboratories
14.5.3. Academic Institutes
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Product Type,
14.7.2. By Application
14.7.3. By End-user
14.7.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. CSL Limited
15.3.1.1. Company Overview
15.3.1.2. Technology, Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Takeda Pharmaceutical Company
15.3.2.1. Company Overview
15.3.2.2. Technology, Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sanquin
15.3.3.1. Company Overview
15.3.3.2. Technology, Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Biotest AG
15.3.4.1. Company Overview
15.3.4.2. Technology, Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. GRIFOLS
15.3.5.1. Company Overview
15.3.5.2. Technology, Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Baxter International Inc.
15.3.6.1. Company Overview
15.3.6.2. Technology, Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Kedrion
15.3.7.1. Company Overview
15.3.7.2. Technology, Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Octapharma AG
15.3.8.1. Company Overview
15.3.8.2. Technology, Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Taibang Biological Group Co., Ltd
15.3.9.1. Company Overview
15.3.9.2. Technology, Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview

List of Tables

Table 01: Plasma Fractionation Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

Table 02: Plasma Fractionation Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 03: Plasma Fractionation Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 04: Plasma Fractionation Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Plasma Fractionation Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Plasma Fractionation Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

Table 07: North America Plasma Fractionation Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 08: North America Plasma Fractionation Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 09: Europe Plasma Fractionation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Plasma Fractionation Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

Table 11: Europe Plasma Fractionation Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 12: Europe Plasma Fractionation Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 13: Asia Pacific Plasma Fractionation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Plasma Fractionation Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

Table 15: Asia Pacific Plasma Fractionation Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 16: Asia Pacific Plasma Fractionation Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 17: Latin America Plasma Fractionation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Plasma Fractionation Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

Table 19: Latin America Plasma Fractionation Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 20: Latin America Plasma Fractionation Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 21: Middle East & Africa Plasma Fractionation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Plasma Fractionation Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

Table 23: Middle East & Africa Plasma Fractionation Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Middle East & Africa Plasma Fractionation Market Size (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Plasma Fractionation Market Size (US$ Mn) and Distribution (%), by Region, 2017–2031

Figure 02: Plasma Fractionation Market Revenue (US$ Mn), by Product Type, 2022

Figure 03: Plasma Fractionation Market Value Share, by Product Type, 2022

Figure 04: Plasma Fractionation Market Revenue (US$ Mn), by Application, 2022

Figure 05: Plasma Fractionation Market Value Share, by Application, 2022

Figure 06: Plasma Fractionation Market Revenue (US$ Mn), by End-user, 2022

Figure 07: Plasma Fractionation Market Value Share, by End-user, 2022

Figure 08: Plasma Fractionation Market Value Share, by Region, 2022

Figure 09: Plasma Fractionation Market Value (US$ Mn) Forecast, 2017–2031

Figure 10: Plasma Fractionation Market Value Share Analysis, by Product Type, 2017–2031

Figure 11: Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031

Figure 12: Plasma Fractionation Market Value Share Analysis, by Application, 2017–2031

Figure 13: Plasma Fractionation Market Attractiveness Analysis, by Application, 2023–2031

Figure 14: Plasma Fractionation Market Value Share Analysis, by End-user, 2017–2031

Figure 15: Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031

Figure 16: Plasma Fractionation Market Value Share Analysis, by Region, 2017–2031

Figure 17: Plasma Fractionation Market Attractiveness Analysis, by Region, 2017–2031

Figure 18: North America Plasma Fractionation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 19: North America Plasma Fractionation Market Attractiveness Analysis, by Country, 2017–2031

Figure 20: North America Plasma Fractionation Market Value Share Analysis, by Country, 2017–2031

Figure 21: North America Plasma Fractionation Market Value Share Analysis, by Product Type, 2017–2031

Figure 22: North America Plasma Fractionation Market Value Share Analysis, by Application, 2017–2031

Figure 23: North America Plasma Fractionation Market Value Share Analysis, by End-user, 2017–2031

Figure 24: North America Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031

Figure 25: North America Plasma Fractionation Market Attractiveness Analysis, by Application, 2023–2031

Figure 26:North America Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031

Figure 27: Europe Plasma Fractionation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 28: Europe Plasma Fractionation Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 29: Europe Plasma Fractionation Market Value Share Analysis, by Country/Sub-region, 2017–2031

Figure 30: Europe Plasma Fractionation Market Value Share Analysis, by Product Type, 2017–2031

Figure 31: Europe Plasma Fractionation Market Value Share Analysis, by Application, 2017–2031

Figure 32: Europe Plasma Fractionation Market Value Share Analysis, by End-user, 2017–2031

Figure 33: Europe Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031

Figure 34: Europe Plasma Fractionation Market Attractiveness Analysis, by Application, 2023–2031

Figure 35: Europe Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031

Figure 36: Asia Pacific Plasma Fractionation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 37: Asia Pacific Plasma Fractionation Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 38: Asia Pacific Plasma Fractionation Market Value Share Analysis, by Country/Sub-region, 2017–2031

Figure 39: Asia Pacific Plasma Fractionation Market Value Share Analysis, by Product Type, 2017–2031

Figure 40: Asia Pacific Plasma Fractionation Market Value Share Analysis, by Application, 2017–2031

Figure 41: Asia Pacific Plasma Fractionation Market Value Share Analysis, by End-user, 2017–2031

Figure 42: Asia Pacific Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031

Figure 43: Asia Pacific Plasma Fractionation Market Attractiveness Analysis, by Application, 2023–2031

Figure 44: Asia Pacific Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031

Figure 45: Latin America Plasma Fractionation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 46: Latin America Plasma Fractionation Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 47: Latin America Plasma Fractionation Market Value Share Analysis, by Country/Sub-region, 2017–2031

Figure 48: Latin America Plasma Fractionation Market Value Share Analysis, by Product Type, 2017–2031

Figure 49: Latin America Plasma Fractionation Market Value Share Analysis, by Application, 2017–2031

Figure 50: Latin America Plasma Fractionation Market Value Share Analysis, by End-user, 2017–2031

Figure 51: Latin America Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031

Figure 52: Latin America Plasma Fractionation Market Attractiveness Analysis, by Application, 2023–2031

Figure 53: Latin America Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031

Figure 54: Middle East & Africa Plasma Fractionation Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 55: Middle East & Africa Plasma Fractionation Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 56: Middle East & Africa Plasma Fractionation Market Value Share Analysis, by Country/Sub-region, 2017–2031

Figure 57: Middle East & Africa Plasma Fractionation Market Value Share Analysis, by Product Type, 2017–2031

Figure 58: Middle East & Africa Plasma Fractionation Market Value Share Analysis, by Application, 2017–2031

Figure 59: Middle East & Africa Plasma Fractionation Market Value Share Analysis, by End-user, 2017–2031

Figure 60: Middle East & Africa Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031

Figure 61: Middle East & Africa Plasma Fractionation Market Attractiveness Analysis, by Application, 2023–2031

Figure 62: Middle East & Africa Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031

△ 一番上に戻る